サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1787190

mRNA治療薬の世界市場

mRNA Therapeutics

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
mRNA治療薬の世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

mRNA治療薬の世界市場、2030年には米国で345億米ドルに達する見込み

2024年に133億米ドルと推定されるmRNA治療薬の世界市場は、2024～2030年の分析期間においてCAGR 17.1%で成長し、2030年には345億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである予防製品は、CAGR18.3%を記録し、分析期間終了時には256億米ドルに達すると予測されます。治療用製品セグメントの成長率は、分析期間中CAGR 14.2%と推定されます。

米国市場は36億米ドルと推定、中国はCAGR 22.8％で成長予測

米国のmRNA治療薬市場は2024年に36億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR22.8%を牽引し、2030年までに77億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ12.6%と15.5%と予測されています。欧州では、ドイツがCAGR約13.7%で成長すると予測されています。

世界のmRNA治療薬市場- 主要動向と促進要因のまとめ

mRNA治療薬は医薬品開発と疾患治療にどのような革命をもたらしているか？

mRNA治療薬の台頭は、医薬品開発の状況を根本的に変え、感染症やがんから遺伝性疾患や希少疾患まで、幅広い疾患を治療するための強力なプラットフォームを提供しています。複雑な製造工程や細胞培養システムを必要とする従来の生物製剤とは異なり、mRNAベースの治療薬は合成メッセンジャーRNAを活用し、治療用タンパク質を体内で直接産生するよう細胞に指示します。このアプローチにより、医薬品開発のタイムラインが大幅に短縮され、疾患経路を標的とする際の精度が向上します。COVID-19 mRNAワクチンの画期的な成功は、この技術のスピードと柔軟性を実証し、mRNAの応用をワクチン以外にも拡大することを目指した研究の急増につながりました。事実上あらゆるタンパク質をmRNA配列にコード化できることから、この技術は個人の遺伝子プロファイルに合わせた治療が可能な個別化医療の有望なツールとして位置づけられています。さらに、脂質ナノ粒子（LNP）送達システムの進歩により、mRNA治療薬の安定性と標的送達が改善され、分解や免疫原性に関連する以前の課題に対処しています。製薬会社や研究機関がmRNAベースのソリューションへの投資を続ける中、自己免疫疾患、心血管系疾患、神経変性疾患などの治療の可能性は急速に拡大しており、mRNA治療薬は現代のバイオテクノロジーにおいて最もダイナミックな分野の一つとなっています。

どのような技術の進歩がmRNAドラッグの有効性とデリバリーを高めているのか？

mRNA治療薬の急速な進化は、製剤化、デリバリー技術、配列最適化の進歩に大きく左右されています。最も重要なブレークスルーの一つは、mRNAの安定性を高め、不要な免疫反応を抑えるN1-メチルシュードウリジンなどの化学修飾ヌクレオチドの開発です。体外転写（IVT）プロセスの改良により、mRNAの収量と純度が向上し、炎症反応の引き金となる二本鎖RNAの混入が減少しました。脂質ナノ粒子（LNP）キャリアの改良もまた、mRNAデリバリーの改善において重要な役割を果たしており、治療ペイロードが標的組織に高効率で到達することを保証すると同時に、標的外への影響を最小限に抑えています。調査チームは現在、組織特異性と治療効果の持続性をさらに高めるため、ポリマーベースのナノ粒子、エクソソーム由来の小胞、ペプチドベースの製剤など、次世代のデリバリーシステムを模索しています。さらに、自己増幅型mRNA（saRNA）の出現により、mRNA濃度を下げて治療用タンパク質を生産できるようになり、より低用量でより長持ちする治療の新たな可能性が開かれました。人工知能（AI）や機械学習が創薬に組み込まれるにつれ、予測モデリングがmRNAの配列やデリバリー戦略の最適化に利用され、mRNAを用いた新規治療法の開発が加速しています。このような技術的進歩は、mRNA治療薬の範囲を拡大し、複数の疾患領域にわたる新たな治療パラダイムを解き放つと期待されています。

規制と製造の課題はmRNA治療薬市場にどのような影響を与えていますか？

mRNA治療薬の大きな可能性にもかかわらず、業界は規制と製造の課題に直面しています。mRNA製造は高度に専門化されているため、特に原材料の調達、試験管内転写、精製プロセスにおいて、厳格な品質管理対策が要求されます。FDAやEMAのような規制機関は、製品の安定性、免疫原性、製造の拡張性に重点を置いたmRNA治療薬の新しいガイドラインを導入しています。製造管理及び品質管理基準（GMP）に準拠した製造施設の必要性から、mRNA医薬品の製造に特化した開発製造受託機関（CDMO）の需要が高まっています。しかし、ヌクレオチド、キャッピング試薬、脂質担体などの主要成分の世界サプライチェーンは依然として途絶えやすく、大規模製造のリスクとなっています。さらに、個々の患者用にカスタマイズされた製剤を必要とするがんワクチンなどの個別化mRNA療法については、規制の枠組みがまだ発展途上です。また、mRNAベースの医薬品は、世界の流通のためにコールドチェーン保管や高度なロジスティクスを必要とすることが多いため、製造コストも重要な課題です。このような課題に対処するためには、バイオテクノロジー企業、規制当局、製造パートナーが継続的に協力し、mRNA治療薬が世界規模で効率的かつ安全に開発・流通できるようにする必要があります。

mRNA治療薬市場を促進する主な成長要因は？

mRNA治療薬市場の成長は、バイオテクノロジー研究への投資の増加、ワクチン以外のアプリケーションの拡大、mRNAデリバリーシステムの技術的進歩など、いくつかの要因によってもたらされます。mRNAベースのCOVID-19ワクチンの成功は、mRNA研究への資金を大幅に後押しし、がん、代謝性疾患、インフルエンザ、HIV、ジカウイルスなどの感染症に対するmRNA治療を調査する臨床試験の流入につながっています。また、個別化医療の台頭は、患者が特定の腫瘍抗原を標的としたカスタマイズ治療を受けるmRNAベースのがんワクチンへの関心を加速させています。さらに、AIを活用した創薬の採用が拡大していることで、mRNAの配列設計が合理化され、製剤が最適化され、開発期間が短縮されています。分散型ワクチン生産と地域製造ハブに対する需要の高まりは、mRNA生産施設への投資に拍車をかけ、市場拡大をさらに後押ししています。脂質ナノ粒子と代替デリバリーシステムの継続的な改良により、mRNA医薬品の有効性と安全性が向上し、より広範な臨床採用が推進されています。さらに、パンデミックへの備えとバイオ医薬品のイノベーションに焦点を当てた政府の取り組みが、mRNA治療薬に資金と規制上の支援を提供しています。新たな適応症が出現し、製造能力が向上するにつれて、mRNA治療薬市場は持続的な成長を遂げ、多くの疾患の治療展望に革命をもたらし、mRNA技術を次世代医療の礎として位置づけています。

セグメント

製品タイプ（予防製品、治療製品）、用途（感染症用途、がん用途、希少遺伝子疾患用途、呼吸器疾患用途、その他用途）、最終用途（病院・クリニック最終用途、研究機関最終用途、その他最終用途）

調査対象企業の例

  • Abogen Biosciences
  • Alnylam Pharmaceuticals
  • Anima Biotech
  • Arcturus Therapeutics Holdings Inc.
  • BioNTech SE
  • Comanche Biopharma
  • CureVac N.V.
  • eTheRNA Immunotherapies NV
  • Ethris GmbH
  • EXACIS Biotherapeutics
  • Gritstone bio, Inc.
  • HC Bioscience
  • Inflammatix, Inc.
  • Ionis Pharmaceuticals
  • Moderna, Inc.
  • Nutcracker Therapeutics
  • Orna Therapeutics
  • ReCode Therapeutics
  • Strand Therapeutics
  • Translate Bio（acquired by Sanofi）

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32236

Global mRNA Therapeutics Market to Reach US$34.5 Billion by 2030

The global market for mRNA Therapeutics estimated at US$13.3 Billion in the year 2024, is expected to reach US$34.5 Billion by 2030, growing at a CAGR of 17.1% over the analysis period 2024-2030. Prophylactic Products, one of the segments analyzed in the report, is expected to record a 18.3% CAGR and reach US$25.6 Billion by the end of the analysis period. Growth in the Therapeutic Products segment is estimated at 14.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 22.8% CAGR

The mRNA Therapeutics market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.7 Billion by the year 2030 trailing a CAGR of 22.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.6% and 15.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.7% CAGR.

Global mRNA Therapeutics Market - Key Trends & Drivers Summarized

How Are mRNA Therapeutics Revolutionizing Drug Development and Disease Treatment?

The rise of mRNA therapeutics has fundamentally changed the landscape of drug development, offering a powerful platform for treating a wide range of diseases, from infectious diseases and cancer to genetic disorders and rare conditions. Unlike traditional biologics, which require complex production processes and cell culture systems, mRNA-based therapies leverage synthetic messenger RNA to instruct cells to produce therapeutic proteins directly within the body. This approach significantly accelerates drug development timelines and enhances precision in targeting disease pathways. The groundbreaking success of mRNA COVID-19 vaccines demonstrated the speed and flexibility of this technology, leading to a surge in research efforts aimed at expanding mRNA applications beyond vaccines. The ability to encode virtually any protein into an mRNA sequence has positioned this technology as a promising tool for personalized medicine, where treatments can be tailored to an individual’s genetic profile. Additionally, advancements in lipid nanoparticle (LNP) delivery systems have improved the stability and targeted delivery of mRNA therapeutics, addressing previous challenges related to degradation and immunogenicity. As pharmaceutical companies and research institutions continue to invest in mRNA-based solutions, the potential for treating conditions such as autoimmune diseases, cardiovascular disorders, and neurodegenerative conditions is rapidly expanding, making mRNA therapeutics one of the most dynamic areas in modern biotechnology.

What Technological Advancements Are Enhancing the Efficacy and Delivery of mRNA Drugs?

The rapid evolution of mRNA therapeutics is largely driven by advancements in formulation, delivery technologies, and sequence optimization. One of the most significant breakthroughs has been the development of chemically modified nucleotides, such as N1-methylpseudouridine, which enhance mRNA stability and reduce unwanted immune responses. Improved in vitro transcription (IVT) processes have increased mRNA yield and purity, reducing the presence of double-stranded RNA contaminants that can trigger inflammatory responses. The refinement of lipid nanoparticle (LNP) carriers has also played a crucial role in improving mRNA delivery, ensuring that the therapeutic payload reaches target tissues with high efficiency while minimizing off-target effects. Researchers are now exploring next-generation delivery systems, including polymer-based nanoparticles, exosome-derived vesicles, and peptide-based formulations, to further enhance tissue specificity and prolonged therapeutic effects. Additionally, the emergence of self-amplifying mRNA (saRNA) has opened new possibilities for lower-dose, longer-lasting treatments by enabling the production of therapeutic proteins at reduced mRNA concentrations. As artificial intelligence (AI) and machine learning are integrated into drug discovery, predictive modeling is being used to optimize mRNA sequences and delivery strategies, accelerating the development of novel mRNA-based therapies. These technological advancements are expected to expand the scope of mRNA therapeutics, unlocking new treatment paradigms across multiple disease areas.

How Are Regulatory and Manufacturing Challenges Impacting the mRNA Therapeutics Market?

Despite the immense potential of mRNA therapeutics, the industry faces regulatory and manufacturing challenges that must be addressed to enable widespread adoption. The highly specialized nature of mRNA production requires stringent quality control measures, particularly in raw material sourcing, in vitro transcription, and purification processes. Regulatory agencies such as the FDA and EMA have introduced new guidelines for mRNA therapeutics, focusing on product stability, immunogenicity, and manufacturing scalability. The need for Good Manufacturing Practice (GMP)-compliant production facilities has increased demand for contract development and manufacturing organizations (CDMOs) that specialize in mRNA drug production. However, the global supply chain for key components such as nucleotides, capping reagents, and lipid carriers remains vulnerable to disruptions, posing risks to large-scale manufacturing. Additionally, regulatory frameworks are still evolving for personalized mRNA therapies, such as cancer vaccines, which require customized formulations for individual patients. Another key challenge is the cost of production, as mRNA-based drugs often require cold-chain storage and sophisticated logistics for global distribution. Addressing these challenges will require continued collaboration between biotech companies, regulatory agencies, and manufacturing partners to ensure that mRNA therapeutics can be developed and distributed efficiently and safely on a global scale.

What Are the Key Growth Drivers Propelling the mRNA Therapeutics Market?

The growth in the mRNA therapeutics market is driven by several factors, including increasing investments in biotechnology research, expanding applications beyond vaccines, and technological advancements in mRNA delivery systems. The success of mRNA-based COVID-19 vaccines has significantly boosted funding for mRNA research, leading to an influx of clinical trials investigating mRNA therapies for cancer, metabolic diseases, and infectious diseases such as influenza, HIV, and Zika virus. The rise of personalized medicine has also accelerated interest in mRNA-based cancer vaccines, where patients receive customized treatments targeting specific tumor antigens. Additionally, the growing adoption of AI-driven drug discovery is streamlining mRNA sequence design, optimizing formulations, and reducing development timelines. The increasing demand for decentralized vaccine production and regional manufacturing hubs has spurred investments in mRNA production facilities, further supporting market expansion. The continued refinement of lipid nanoparticles and alternative delivery systems has enhanced the efficacy and safety of mRNA drugs, driving broader clinical adoption. Furthermore, government initiatives focused on pandemic preparedness and biopharmaceutical innovation are providing funding and regulatory support for mRNA therapeutics. As new indications emerge and manufacturing capabilities improve, the mRNA therapeutics market is poised for sustained growth, revolutionizing the treatment landscape for numerous diseases and positioning mRNA technology as a cornerstone of next-generation medicine.

SCOPE OF STUDY:

The report analyzes the mRNA Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Prophylactic Products, Therapeutic Products); Application (Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abogen Biosciences
  • Alnylam Pharmaceuticals
  • Anima Biotech
  • Arcturus Therapeutics Holdings Inc.
  • BioNTech SE
  • Comanche Biopharma
  • CureVac N.V.
  • eTheRNA Immunotherapies NV
  • Ethris GmbH
  • EXACIS Biotherapeutics
  • Gritstone bio, Inc.
  • HC Bioscience
  • Inflammatix, Inc.
  • Ionis Pharmaceuticals
  • Moderna, Inc.
  • Nutcracker Therapeutics
  • Orna Therapeutics
  • ReCode Therapeutics
  • Strand Therapeutics
  • Translate Bio (acquired by Sanofi)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • mRNA Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Investment in mRNA Technology for Therapeutic Development Drives Market Growth
    • Surge in Global Demand for mRNA-Based Vaccines Expands Market Opportunity for mRNA Therapeutics
    • Accelerated Research and Development in mRNA-Based Cancer Therapies Expands Market Horizons
    • Regulatory Support and Fast-Track Approvals for mRNA Therapies Strengthen Market Confidence and Adoption
    • Technological Advancements in mRNA Delivery Systems Propel Growth in Therapeutic Applications
    • Rising Consumer Demand for Personalized Medicine Drives Adoption of mRNA Therapeutics in Tailored Treatment Plans
    • The Emergence of mRNA-based Infectious Disease Treatments Spells Long-term Growth for the Therapeutics Market
    • Increasing Use of mRNA Vaccines in Global Immunization Campaigns Accelerates Market Adoption
    • The Shift Toward Preventive Healthcare and Proactive Disease Management Boosts Demand for mRNA Therapeutics
    • Growing Integration of mRNA Technology into Cancer Immunotherapies Expands Market Opportunity
    • Increasing Collaborations Between Biopharma Companies and Research Institutions Fuel mRNA Therapeutics Innovation
    • The Global COVID-19 Pandemic Drives Significant Investment and Infrastructure Development for mRNA Therapeutics
    • Expansion of Clinical Trials for mRNA Therapeutics in Rare and Genetic Diseases Spurs Market Potential
    • Rising Focus on the Safety and Efficacy of mRNA-based Therapies Strengthens Consumer Confidence and Adoption
    • The Growing Role of Artificial Intelligence and Machine Learning in mRNA Therapeutics Development Drives Innovation
    • Expansion of Manufacturing Capabilities for mRNA-based Drugs Increases Market Accessibility and Scalability
    • Increasing Global Health Initiatives and Public-Private Partnerships Accelerates Demand for mRNA Therapeutics
    • The Rise of mRNA-based Protein Replacement Therapies Strengthens Market Demand for mRNA in Genetic Disorders
    • Regulatory and Ethical Issues Surrounding mRNA Technology Drive Innovation in Safety Protocols and Guidelines
    • Increasing Interest in mRNA as a Platform for Targeted Therapies Expands Addressable Market Opportunity for Therapeutic Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World mRNA Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Prophylactic Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Prophylactic Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Therapeutic Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Therapeutic Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Rare Genetic Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Rare Genetic Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Respiratory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Respiratory Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • JAPAN
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • CHINA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • EUROPE
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • FRANCE
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • GERMANY
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 82: Spain Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Spain 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 84: Spain Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Spain 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 88: Russia Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Russia 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 90: Russia Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Russia 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of Europe 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of Europe 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Asia-Pacific 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • AUSTRALIA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 106: Australia Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Australia 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 108: Australia Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Australia 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • INDIA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 112: India Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: India 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 114: India Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: India 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 118: South Korea Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: South Korea 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 120: South Korea Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: South Korea 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 124: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 126: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • LATIN AMERICA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 130: Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 131: Latin America 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 132: Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Latin America 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 136: Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Latin America 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 138: Argentina Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Argentina 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 142: Argentina Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Argentina 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • BRAZIL
    • TABLE 144: Brazil Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 145: Brazil 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 148: Brazil Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 149: Brazil 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • MEXICO
    • TABLE 150: Mexico Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 151: Mexico 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 154: Mexico Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 155: Mexico 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 156: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 157: Rest of Latin America 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 160: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 161: Rest of Latin America 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • MIDDLE EAST
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 162: Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 163: Middle East 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 166: Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 167: Middle East 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 168: Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 169: Middle East 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 172: Iran Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 173: Iran 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 174: Iran Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 175: Iran 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 178: Israel Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 179: Israel 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 180: Israel Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 181: Israel 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 184: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 185: Saudi Arabia 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 186: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 187: Saudi Arabia 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 190: UAE Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 191: UAE 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 192: UAE Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 193: UAE 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 196: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 197: Rest of Middle East 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 198: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 199: Rest of Middle East 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • AFRICA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 202: Africa Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 203: Africa 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 204: Africa Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 205: Africa 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030

IV. COMPETITION